Endothelin Receptor Antagonists in Kidney Disease [PDF]
International Journal of Molecular Sciences, 2023 Endothelin (ET) is found to be increased in kidney disease secondary to hyperglycaemia, hypertension, acidosis, and the presence of insulin or proinflammatory cytokines. In this context, ET, via the endothelin receptor type A (ETA) activation, causes sustained vasoconstriction of the afferent arterioles that produces deleterious effects such as ...
Irène Martinez-Diaz +2 more
exaly +5 more sources
Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type-5 inhibitors [PDF]
Pulmonary Circulation, 2020 Adherence to therapy for pulmonary arterial hypertension is essential to optimize patient outcomes, but data on real-world adherence to different pulmonary arterial hypertension drug classes are limited.
Robert P. Frantz +6 more
doaj +2 more sources
The role of endothelin receptor antagonists in kidney disease [PDF]
Renal FailureKidney diseases are among the most prevalent conditions worldwide, impacting over 850 million individuals. They are categorized into acute kidney injury and chronic kidney disease. Current preclinical and clinical trials have demonstrated that endothelin
Xiaoting Ma +5 more
doaj +2 more sources
Endothelin receptor antagonists target EDNRB and modulate the progression of idiopathic pulmonary fibrosis via anoikis-related genes [PDF]
Frontiers in MedicineIdiopathic pulmonary fibrosis (IPF) progression involves dysregulation of anoikis-related mechanisms, though the precise molecular drivers remain unclear.
Pengfei Ning +4 more
doaj +2 more sources
Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand? [PDF]
Vascular Health and Risk Management, 2018 Michele Correale,1 Armando Ferraretti,2 Ilenia Monaco,3 Davide Grazioli,1 Matteo Di Biase,4 Natale Daniele Brunetti3 1Department of Cardiology, Ospedali Riuniti University Hospital, Foggia, 2Cardiology Unit, “Caduti in guerra” Hospital ...
Correale M +5 more
doaj +2 more sources
The gastrointestinal endothelin system: receptors, cellular actions, and involvement in gastrointestinal disorders [PDF]
Gastroenterology ReviewThe gastrointestinal endothelin system regulates vital processes including motility, secretion, sensation, and inflammation. Endothelin-1 acts via endothelin A and B receptors expressed on diverse intestinal cells.
Arjun Singh, Rajvir Singh
doaj +2 more sources
Endothelin receptor antagonists (ERAs) can potentially be used as therapeutic drugs to reduce hypertension caused by small molecule tyrosine kinase inhibitors (TKIs) [PDF]
Frontiers in PharmacologyThe emergence of targeted anti-tumor drugs has significantly prolonged the lifespan and improved the prognosis of cancer patients. Among these drugs, vascular endothelial growth factor (VEGF) inhibitors, particularly novel small molecule tyrosine kinase ...
Qingjian He +11 more
doaj +2 more sources
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016 BackgroundEvidence of the clinical safety of endothelin receptor antagonists (ERAs) is limited and derived mainly from individual trials; therefore, we conducted a meta‐analysis.
Anhua Wei +6 more
doaj +3 more sources
Progress in mechanistic and clinical translational research of endothelin A receptor antagonists in the treatment of diabetic kidney disease: a narrative review [PDF]
Frontiers in EndocrinologyBackgroundDiabetic kidney disease (DKD) remains a leading cause of end-stage renal disease worldwide. Despite advances in renin–angiotensin–aldosterone system (RAAS) inhibitors, sodium–glucose cotransporter 2 (SGLT2) inhibitors, and mineralocorticoid ...
Muqin Li +21 more
doaj +2 more sources
Endothelin receptor antagonists in diabetic and non-diabetic chronic kidney disease [PDF]
CKJ: Clinical Kidney JournalAnnette Bruchfeld +2 more
exaly +2 more sources